{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T08:00:35Z","timestamp":1649059235064},"reference-count":33,"publisher":"FapUNIFESP (SciELO)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Gastroenterol."],"published-print":{"date-parts":[[2015,3]]},"abstract":"<jats:p> ABSTRACT Biosimilars are not generic drugs. These are more complex medications than small molecules, with identical chemical structures of monoclonal antibodies that lost their patency over time. Besides identical to the original product at the end, the process of achieving its final forms differs from the one used in the reference products. These differences in the formulation process can alter final outcomes such as safety and efficacy of the drugs. Recently, a biosimilar of Infliximab was approved in some countries, even to the management of inflammatory bowel diseases. However, this decision was based on studies performed in rheumatologic conditions such as rheumatoid arthritis and ankylosing spondylitis. Extrapolation of the indications from rheumatologic conditions was done for Crohn\u2019s disease and ulcerative colitis based on these studies. In this article, the authors explain possible different mechanisms in the pathogenesis between rheumatologic conditions and inflammatory bowel diseases, that can lead to different actions of the medications in different diseases. The authors also alert the gastroenterological community for the problem of extrapolation of indications, and explain in full details the reasons for being care with the use of biosimilars in inflammatory bowel diseases without specific data from trials performed in this scenario.<\/jats:p>","DOI":"10.1590\/s0004-28032015000100016","type":"journal-article","created":{"date-parts":[[2017,3,8]],"date-time":"2017-03-08T13:56:24Z","timestamp":1488981384000},"page":"76-80","source":"Crossref","is-referenced-by-count":5,"title":["BIOSIMILARS IN INFLAMMATORY BOWEL DISEASES: an important moment for Brazilian gastroenterologists"],"prefix":"10.1590","volume":"52","author":[{"given":"F\u00e1bio Vieira","family":"TEIXEIRA","sequence":"first","affiliation":[{"name":"Cl\u00ednica Gastrosa\u00fade,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo Gustavo","family":"KOTZE","sequence":"additional","affiliation":[{"name":"Hospital Universit\u00e1rio Cajuru - SeCoHUC - PUCPR,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aderson Omar Mour\u00e3o Cintra","family":"DAMI\u00c3O","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo - FMUSP,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sender Jankiel","family":"MISZPUTEN","sequence":"additional","affiliation":[{"name":"Escola Paulista de Medicina - UNIFESP,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"key":"ref1","series-title":"Registro de Produtos Biol\u00f3gicos. Bases Legais e Guias - Colet\u00e2nea. Resolu\u00e7\u00e3o - RDC n 55, de 16 de dezembro de 2010","year":"2010"},{"issue":"1","key":"ref2","first-page":"127","article-title":"Biossimilares necessitam de dados cl\u00ednicos comparativos cientificamente confi\u00e1veis","volume":"53","author":"Azevedo VF","year":"2013","journal-title":"Rev Bras Reumatol"},{"key":"ref3","series-title":"Biologics Price Competition and Innovation Act of 2009, H.R. 3590-687, Licensure of Biological Products as Biosimilar or Interchangeable","year":"2009"},{"key":"ref4","series-title":"Biosimilar News. [Internet]","volume-title":"World\u2019s first biosimilar antibody is approved in Korea; 2012 Jul 23","year":"2012"},{"issue":"5","key":"ref5","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.biologicals.2011.06.021","article-title":"Current development in regulation of similar biotherapeutic products in Brazil","volume":"39","author":"Castanheira LG","year":"2011","journal-title":"Biologicals"},{"key":"ref6","journal-title":"INFLECTRA (infliximab). Product Monograph"},{"key":"ref7","journal-title":"REMSIMA (infliximab). Product Monograph"},{"key":"ref8","first-page":"45","article-title":"The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis","volume":"65","author":"Chen HA","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"ref9","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.crohns.2014.06.007","article-title":"Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn\u2019s and Colitis Organization","volume":"8","author":"Danese S","year":"2014","journal-title":"J Crohns Colitis"},{"issue":"7","key":"ref10","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.crohns.2013.03.011","article-title":"ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD)","volume":"7","author":"Danese S","year":"2013","journal-title":"J Crohns Colitis"},{"key":"ref11","article-title":"Biological and biosimilars: is similar the same?","volume":"8","author":"Decleck PF","year":"2013","journal-title":"J Crohns Colitis"},{"issue":"10","key":"ref12","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1155\/2013\/327120","article-title":"Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics","volume":"27","author":"Devlin SM","year":"2013","journal-title":"Can J Gastroenterol"},{"key":"ref13","series-title":"European Medicines Agency recommends approval of first two monoclonal antibody biosimilars. [Internet]. Recommendation marks extension of biosimilar concept to new product-class"},{"key":"ref14","series-title":"Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use, November 2012","year":"2012"},{"key":"ref15","series-title":"Biosimilar medicines, 2012","year":"2012"},{"key":"ref16","year":"2012","journal-title":"European Assessment Reports for authorized medicinal products for human use. 2012"},{"key":"ref17","series-title":"Guidelines on evaluation of similar biotherapeutic products","year":"2009"},{"issue":"4","key":"ref18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.biologicals.2014.05.005","article-title":"The challenge of indication extrapolation for infliximab biosimilars","volume":"42","author":"Feagan BG","year":"2014","journal-title":"Biologicals"},{"issue":"6","key":"ref19","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1136\/gutjnl-2012-303824","article-title":"Biosimilars in IBD: hope or expectation?","volume":"62","author":"Gecse KB","year":"2013","journal-title":"Gut"},{"issue":"10","key":"ref20","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1155\/2013\/634176","article-title":"Subsequent entry biologics e opportunities and challenges","volume":"27","author":"Ghosh S","year":"2013","journal-title":"Can J Gastroenterol"},{"issue":"4","key":"ref21","first-page":"A697","article-title":"Neutralization of soluble and membrane tumor necrosis factor-alpha (TNF-alpha) by infliximab, adalimumab, or certolizumab pegol using P55 or P75 TNF-alpha receptor- specific bioassays","volume":"130","author":"Gramlick A","year":"2006","journal-title":"Gastroenterology"},{"key":"ref22","series-title":"Guidance for Industry. [Internet]. Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product"},{"key":"ref23","series-title":"Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product: Inflectra"},{"key":"ref24","series-title":"Guidance for sponsors: information and submission requirements for subsequent entry biologics (SEBs)","year":"2010"},{"key":"ref25","series-title":"REMICADE (infliximab) summary of product characteristics","year":"2013"},{"key":"ref26","series-title":"Guidelines on the evaluation of biosimilar products","year":"2010"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1208\/s12248-013-9534-y","article-title":"Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars?","volume":"16","author":"Lee H","year":"2013","journal-title":"AAPS J"},{"issue":"23","key":"ref28","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"354","author":"McInnes IB","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"ref29","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","article-title":"A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study","volume":"72","author":"Park W","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"ref30","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.crohns.2013.12.002","article-title":"Biosimilars in Crohn\u2019s disease","volume":"8","author":"Scheinberg M","year":"2014","journal-title":"J Crohns Colitis"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review","volume":"117","author":"Tracey D","year":"2008","journal-title":"Pharmacol Ther"},{"issue":"3","key":"ref32","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s40259-013-0020-y","article-title":"Development and regulation of bio- similars: current status and future challenges","volume":"27","author":"Tsiftsoglou AS","year":"2013","journal-title":"BioDrugs"},{"issue":"10","key":"ref33","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","article-title":"A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT- P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study","volume":"72","author":"Yoo DH","year":"2013","journal-title":"Ann Rheum Dis"}],"container-title":["Arquivos de Gastroenterologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/ag\/v52n1\/0004-2803-ag-52-01-76.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T00:19:00Z","timestamp":1495498740000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-28032015000100016&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S0004-28032015000100016"],"URL":"https:\/\/doi.org\/10.1590\/s0004-28032015000100016","relation":{},"ISSN":["0004-2803"],"issn-type":[{"value":"0004-2803","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3]]}}}